Clinical Question
What is the current regulatory status of commonly compounded peptides in the United States, and what emerging safety signals have been identified in recent clinical data and postmarketing surveillance?
Evidence Snapshot
- Regulatory Status: Multiple peptides including BPC-157, TB-500, and CJC-1295 are currently listed under FDA Category 2 (Bulk Substances), rendering them ineligible for routine compounding due to safety risks.
- Safety Signals (Semaglutide): Strong signals for gastrointestinal events (nausea, vomiting, delayed gastric emptying); emerging signals for NAION (96 cases) and pulmonary aspiration.
- Clinical Trial Outcomes: Phase III data for Semaglutide shows 14.9% weight loss (STEP 1) and 20% MACE reduction (SELECT); Phase III data for Thymosin Alpha-1 in sepsis showed no mortality reduction.
- Regulatory Warnings: Multiple warning letters issued in 2020 to entities such as Tailor Made Compounding and Predator Nutrition regarding unapproved peptide substances.
What the Research Shows
Regulatory and Compounding Status As of March 2026, the FDA has classified several peptides under Category 2 of the bulk drug substances list for 503A (compounding pharmacies) and 503B (outsourcing facilities). BPC-157 was designated Category 2 in September 2023 due to significant safety risks, including immunogenicity concerns and a lack of clinical safety data. Similarly, TB-500 remains under Category 2 as the FDA cites immunogenicity risks and an absence of human exposure data.
Several peptides that were nominated for compounding have seen recent changes in status. Between September 2023 and September 2024, nominations for AOD-9604, Ipamorelin, and Selank were withdrawn. CJC-1295 was removed following nomination withdrawal, with the FDA citing safety issues such as increased heart rate. Thymosin Alpha-1 was removed from Category 2 in September 2024 pending advisory review, though it remains a substance of concern under interim policy. While Thymosin Alpha-1 is approved in over 35 countries as Zadaxin, it is not FDA-approved in the United States. Similarly, Selank and Semax are approved in Russia, the latter specifically for stroke, but neither has FDA approval.
Postmarketing Safety Signals Surveillance data for Semaglutide reveals a complex safety profile across several organ systems. Gastrointestinal events remain the most frequent, with 187,757 GLP-1 RA reports through 2023. These include strong, dose-dependent signals for nausea and vomiting, and a moderate signal for acute pancreatitis. A strong signal for delayed gastric emptying has also been identified, which may impact the absorption of oral medications and presents pre-surgical concerns.
Emerging safety signals for Semaglutide include Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), with 96 cases reported through December 2024; this is currently under EMA review as of January 2025. Additionally, the Ozempic label was updated in 2025 to include pulmonary aspiration risk during general anesthesia. While suicidal ideation is listed in the label (Section 5.9), current FDA data do not support a higher risk compared to background rates.
Clinical Trial Findings Clinical evidence for approved and investigational peptides continues to evolve. In the STEP 1 trial (NCT03548935), Semaglutide demonstrated 14.9% weight loss in obesity, while the SELECT trial (NCT03574597) showed a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide demonstrated 22.5% weight loss in the SURMOUNT-1 trial and was found superior to semaglutide in the SURMOUNT-5 head-to-head trial. Retatrutide showed 24.2% weight loss at 12mg in Phase II trials, with Phase III (TRIUMPH-3) ongoing. For non-metabolic indications, Thymosin Alpha-1 failed to reduce mortality in a Phase III sepsis trial (NCT02867267).
Mechanism
The provided data does not include pharmacological mechanisms of action for these substances beyond the clinical outcomes and safety signals noted.
Limitations of the Evidence
A significant limitation in the current evidence is the lack of human exposure and safety data for several compounded peptides, including BPC-157 and TB-500. For many substances, such as GHK-Cu, GHRP-2, and Semax, there is no FDA-approved injectable drug version, and safety evaluations are based on immunogenicity concerns rather than large-scale clinical trials. The signal for NAION associated with Semaglutide is based on 96 cases and remains under formal review; the median onset is reported as 186 days, limiting conclusions on long-term risk. Additionally, the status of Thymosin Alpha-1 as a substance of concern persists despite its removal from Category 2 pending advisory review.
Clinical Takeaway
Physicians should note that BPC-157, TB-500, CJC-1295, and others are currently ineligible for routine compounding due to FDA safety and immunogenicity concerns. For approved GLP-1 receptor agonists, clinical management should prioritize dose escalation to mitigate gastrointestinal effects and monitor for emerging risks related to pulmonary aspiration and NAION. Regulatory status for several peptides remains in flux as nominations are withdrawn or reviewed by advisory boards.
Sources
- FDA Regulatory Status Records (March 2026)
- FAERS Safety Signal Database (2023-2025)
- Clinical Trial Records: NCT03548935, NCT03574597, NCT04184622, NCT04881706, NCT02867267, NCT00451282
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.